BZPEERPapers, people, evidence and research paths
Menu

Discover

SearchFind papers, people, topics, institutions and opportunities from one place.GraphSee how papers, authors, topics and evidence connect.

Research tools

HomeContinue from the papers, people and topics that matter now.CollectionsTurn saved papers into reading lists, evidence maps and shareable context.ResearchReconstruct the path that led you from search to paper to question.CollaborationMove from a paper, topic or expert request into a focused thread.PublishCreate full-text research articles with metadata, formulas and versions.

Network

ExpertsFind specialists whose work and reviews explain why they can help.CommunitiesJoin research groups organized around papers, topics and shared evidence.

Opportunities

ListingsBrowse roles, calls and collaborations connected to real research context.

Account

Log inReturn to your saved papers, graph views and active threads.Create accountStart saving papers, building a research trail and joining teams.
Log inCreate account

Source author record

Jeremy M. G. Taylor

Jeremy M. G. Taylor appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record
MethodologyApplications

Catalog footprint

What is connected

7works
2topics
4close collaborators

Actions

Connect this record

Log in to claim
Open graphBrowse works

Research graph

See the researcher in context

Open full explorer

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

7 published item(s)

preprint2022arXiv

Incorporating baseline covariates to validate surrogate endpoints with a constant biomarker under control arm

A surrogate endpoint S in a clinical trial is an outcome that may be measured earlier or more easily than the true outcome of interest T. In this work, we extend causal inference approaches to validate such a surrogate using potential outcomes. The causal association paradigm assesses the relationship of the treatment effect on the surrogate with the treatment effect on the true endpoint. Using the principal surrogacy criteria, we utilize the joint conditional distribution of the potential outcomes T, given the potential outcomes S. In particular, our setting of interest allows us to assume the surrogate under the placebo, S(0), is zero-valued, and we incorporate baseline covariates in the setting of normally-distributed endpoints. We develop Bayesian methods to incorporate conditional independence and other modeling assumptions and explore their impact on the assessment of surrogacy. We demonstrate our approach via simulation and data that mimics an ongoing study of a muscular dystrophy gene therapy.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Kullback-Leibler-Based Discrete Failure Time Models for Integration of Published Prediction Models with New Time-To-Event Dataset

Prediction of time-to-event data often suffers from rare event rates, small sample sizes, high dimensionality and low signal-to-noise ratios. Incorporating published prediction models from large-scale studies is expected to improve the performance of prognosis prediction on internal individual-level time-to-event data. However, existing integration approaches typically assume that underlying distributions from the external and internal data sources are similar, which is often invalid. To account for challenges including heterogeneity, data sharing, and privacy constraints, we propose a discrete failure time modeling procedure, which utilizes a discrete hazard-based Kullback-Leibler discriminatory information measuring the discrepancy between the published models and the internal dataset. Simulations show the advantage of the proposed method compared with those solely based on the internal data or published models. We apply the proposed method to improve prediction performance on a kidney transplant dataset from a local hospital by integrating this small-scale dataset with published survival models obtained from the national transplant registry.

0 citations0 reviewsNo code linkedOpen access
preprint2022arXiv

Understanding the dynamic impact of COVID-19 through competing risk modeling with bivariate varying coefficients

The coronavirus disease 2019 (COVID-19) pandemic has exerted a profound impact on patients with end-stage renal disease relying on kidney dialysis to sustain their lives. Motivated by a request by the U.S. Centers for Medicare & Medicaid Services, our analysis of their postdischarge hospital readmissions and deaths in 2020 revealed that the COVID-19 effect has varied significantly with postdischarge time and time since the onset of the pandemic. However, the complex dynamics of the COVID-19 effect trajectories cannot be characterized by existing varying coefficient models. To address this issue, we propose a bivariate varying coefficient model for competing risks within a cause-specific hazard framework, where tensor-product B-splines are used to estimate the surface of the COVID-19 effect. An efficient proximal Newton algorithm is developed to facilitate the fitting of the new model to the massive Medicare data for dialysis patients. Difference-based anisotropic penalization is introduced to mitigate model overfitting and the wiggliness of the estimated trajectories; various cross-validation methods are considered in the determination of optimal tuning parameters. Hypothesis testing procedures are designed to examine whether the COVID-19 effect varies significantly with postdischarge time and the time since pandemic onset, either jointly or separately. Simulation experiments are conducted to evaluate the estimation accuracy, type I error rate, statistical power, and model selection procedures. Applications to Medicare dialysis patients demonstrate the real-world performance of the proposed methods.

0 citations0 reviewsNo code linkedOpen access
preprint2020arXiv

Using Multiple Imputation to Classify Potential Outcomes Subgroups

With medical tests becoming increasingly available, concerns about over-testing and over-treatment dramatically increase. Hence, it is important to understand the influence of testing on treatment selection in general practice. Most statistical methods focus on average effects of testing on treatment decisions. However, this may be ill-advised, particularly for patient subgroups that tend not to benefit from such tests. Furthermore, missing data are common, representing large and often unaddressed threats to the validity of statistical methods. Finally, it is desirable to conduct analyses that can be interpreted causally. We propose to classify patients into four potential outcomes subgroups, defined by whether or not a patient's treatment selection is changed by the test result and by the direction of how the test result changes treatment selection. This subgroup classification naturally captures the differential influence of medical testing on treatment selections for different patients, which can suggest targets to improve the utilization of medical tests. We can then examine patient characteristics associated with patient potential outcomes subgroup memberships. We used multiple imputation methods to simultaneously impute the missing potential outcomes as well as regular missing values. This approach can also provide estimates of many traditional causal quantities. We find that explicitly incorporating causal inference assumptions into the multiple imputation process can improve the precision for some causal estimates of interest. We also find that bias can occur when the potential outcomes conditional independence assumption is violated; sensitivity analyses are proposed to assess the impact of this violation. We applied the proposed methods to examine the influence of 21-gene assay, the most commonly used genomic test, on chemotherapy selection among breast cancer patients.

0 citations0 reviewsNo code linkedOpen access
preprint2015arXiv

Personalized Screening Intervals for Biomarkers using Joint Models for Longitudinal and Survival Data

Screening and surveillance are routinely used in medicine for early detection of disease and close monitoring of progression. Biomarkers are one of the primarily tools used for these tasks, but their successful translation to clinical practice is closely linked to their ability to accurately predict clinical endpoints during follow-up. Motivated by a study of patients who received a human tissue valve in the aortic position, in this work we are interested in optimizing and personalizing screening intervals for longitudinal biomarker measurements. Our aim in this paper is twofold: First, to appropriately select the model to use at time t, the time point the patient was still event-free, and second, based on this model to select the optimal time point u > t to plan the next measurement. To achieve these two goals we develop measures based on information theory quantities that assess the information we gain for the conditional survival process given the history of the subject that includes both baseline information and his/her accumulated longitudinal measurements.

0 citations0 reviewsNo code linkedOpen access
preprint2014arXiv

Bayesian shrinkage methods for partially observed data with many predictors

Motivated by the increasing use of and rapid changes in array technologies, we consider the prediction problem of fitting a linear regression relating a continuous outcome $Y$ to a large number of covariates $\mathbf {X}$, for example, measurements from current, state-of-the-art technology. For most of the samples, only the outcome $Y$ and surrogate covariates, $\mathbf {W}$, are available. These surrogates may be data from prior studies using older technologies. Owing to the dimension of the problem and the large fraction of missing information, a critical issue is appropriate shrinkage of model parameters for an optimal bias-variance trade-off. We discuss a variety of fully Bayesian and Empirical Bayes algorithms which account for uncertainty in the missing data and adaptively shrink parameter estimates for superior prediction. These methods are evaluated via a comprehensive simulation study. In addition, we apply our methods to a lung cancer data set, predicting survival time ($Y$) using qRT-PCR ($\mathbf {X}$) and microarray ($\mathbf {W}$) measurements.

0 citations0 reviewsNo code linkedOpen access
preprint2012arXiv

Signal extraction and breakpoint identification for array CGH data using robust state space model

Array comparative genomic hybridization(CGH) is a high resolution technique to assess DNA copy number variation. Identifying breakpoints where copy number changes will enhance the understanding of the pathogenesis of human diseases, such as cancers. However, the biological variation and experimental errors contained in array CGH data may lead to false positive identification of breakpoints. We propose a robust state space model for array CGH data analysis. The model consists of two equations: an observation equation and a state equation, in which both the measurement error and evolution error are specified to follow t-distributions with small degrees of freedom. The completely unspecified CGH profiles are estimated by a Markov Chain Monte Carlo(MCMC) algorithm. Breakpoints and outliers are identified by a novel backward selection procedure based on posterior draws of the CGH profiles. Compared to three other popular methods, our method demonstrates several desired features, including false positive rate control, robustness against outliers, and superior power of breakpoint detection. All these properties are illustrated using simulated and real datasets.

0 citations0 reviewsNo code linkedOpen access